OOIR: Observatory of International Research

Papers

(The TQCC of Cephalalgia is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution	162
Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial	88
A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention	79
Headache associated with COVID-19: Frequency, characteristics and association with anosmia and ageusia	71
Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine	70
Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study	70
Isolated intracranial hypertension associated with COVID-19	70
Migraine therapeutics differentially modulate the CGRP pathway	67
Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis	60
Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients	59
Phenotypic characterization of acute headache attributed to SARS-CoV-2: An ICHD-3 validation study on 106 hospitalized patients	58
The presence of headache at onset in SARS-CoV-2 infection is associated with long-term post-COVID headache and fatigue: A case-control study	52
Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis	48
Prevalence of neck pain in migraine: A systematic review and meta-analysis	46
Effect of lockdown during COVID-19 on migraine: A longitudinal cohort study	46
Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials	46
Clinical, oculographic, and vestibular test characteristics of vestibular migraine	45
Characteristics of headache attributed to COVID-19 infection and predictors of its frequency and intensity: A cross sectional study	45
I stay at home with headache. A survey to investigate how the lockdown for COVID-19 impacted on headache in Italian children	44
Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study	43
Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study	43
CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis	43
Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database	41
A systematic review of treatment for patients with burning mouth syndrome	41
Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment – a real-life cohort study	40

Daily persistent headache after a viral illness during a worldwide pandemic may not be a new occurrence: Lessons from the 1890 Russian/Asiatic flu	39
The role of cytokines in migraine: A systematic review	39
Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study	37
Incidence of headache after COVID-19 vaccination in patients with history of headache: A cross-sectional study	36
E-diary use in clinical headache practice: A prospective observational study	36
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial	36
CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine	36
Incidence of spontaneous intracranial hypotension in a community: Beverly Hills, California, 2006–2020	35
Diagnosis and treatment of idiopathic intracranial hypertension	34
Sex differences in prevalence of migraine trigger factors: A cross-sectional study	32
Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks	31
The characteristics of COVID-19 vaccine-related headache: Clues gathered from the healthcare personnel in the pandemic	29
Two hundred and forty-eight cases of visual snow: A review of potential inciting events and contributing comorbidities	27
Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons	27
Interictal amylin levels in chronic migraine patients: A case-control study	27
Photophobia in migraine: A symptom cluster?	27
Headache attributed to SARS-CoV-2 infection, vaccination and the impact on primary headache disorders of the COVID-19 pandemic: A comprehensive review	26
Hypersensitivity to calcitonin gene-related peptide in chronic migraine	25
Post-traumatic headache due to mild traumatic brain injury: Current knowledge and future directions	25
Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society	25
Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label ext	25
COVID-19-related headache and sinonasal inflammation: A longitudinal study analysing the role of acute rhinosinusitis and ICHD-3 classification difficulties in SARS-CoV-2 infection	25
Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial	24
Alopecia as an emerging adverse event to CGRP monoclonal antibodies: Cases Series, evaluation of FAERS, and literature review	23
Pre-treatment non-ictal cephalic allodynia identifies responders to prophylactic treatment of chronic and episodic migraine patients with galcanezumab: A prospective quantitative sensory testing study	23
Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache	23
CGRP monoclonal antibody prevents the loss of diffuse noxious inhibitory controls (DNIC) in a mouse model of post-traumatic headache	23
Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study	22
Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II	22
Prevalence and risk factors of migraine and non-migraine headache in older people – results of the Heinz Nixdorf Recall study	22
The migraine postdrome: Spontaneous and triggered phenotypes	22
How does the brain change in chronic migraine? Developing disease biomarkers	21
Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients	21
Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine	21
Functional magnetic resonance imaging in migraine: A systematic review	21
Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data	20
Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-ana	20
Prevalence and characteristics of Alice in Wonderland Syndrome in adult migraineurs: Perspectives from a tertiary referral headache unit	20
Activation of the trigeminal system as a likely target of SARS-CoV-2 may contribute to anosmia in COVID-19	20
Validation of diagnostic ICHD-3 criteria for menstrual migraine	19
Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine	19
Prevalence of pre-cluster symptoms in episodic cluster headache: Is it possible to predict an upcoming bout?	19
Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial	19
Distinguishing persistent post-traumatic headache from migraine: Classification based on clinical symptoms and brain structural MRI data	19
CGRP measurements in human plasma – a methodological study	19
Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine	19
Premonitory symptoms in migraine from China: A multi-clinic study of 4821 patients	19
Developing an artificial intelligence-based headache diagnostic model and its utility for non-specialists’ diagnostic accuracy	18
Combination of acupuncture and medical training therapy on tension type headache: Results of a randomised controlled pilot study	18
Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature	18

Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications	17
The gut microbiome modulates nitroglycerin-induced migraine-related hyperalgesia in mice	17
New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy	17
Intravenous lacosamide and phenytoin for the treatment of acute exacerbations of trigeminal neuralgia: A retrospective analysis of 144 cases	17
Atrial fibrillation and migraine with aura in young adults with ischemic stroke	17
Comprehensive clinical phenotyping of nitroglycerin infusion induced cluster headache attacks	17
Migraine-attributed burden, impact and disability, and migraine-impacted quality of life: Expert consensus on definitions from a Delphi process	17
A prolactin-dependent sexually dimorphic mechanism of migraine chronification	17
The prevalence of headache disorders in children and adolescents in Iran: a schools-based study	17
Atogepant – an orally-administered CGRP antagonist – attenuates activation of meningeal nociceptors by CSD	17
Neurological and psychiatric comorbidities of migraine: Concepts and future perspectives	17
Nocebo response in human models of migraine: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled, two-way crossover trials in migraine without aura and healthy volunt	17
Real-life treatment of cluster headache in a tertiary headache center – results from the Danish Cluster Headache Survey	17
“Idiopathic” intracranial hypertension: An update from neurointerventional research for clinicians	16
High perceived isolation and reduced social support affect headache impact levels in migraine after the Covid-19 outbreak: A cross sectional survey on chronic and episodic patients	16
Diagnosis of idiopathic intracranial hypertension: A proposal for evidence-based diagnostic criteria	15
A national Swedish case-control study investigating incidence and factors associated with idiopathic intracranial hypertension	15
TOP-PRO study: A randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine	15
Pediatric-onset trigeminal autonomic cephalalgias: A systematic review and meta-analysis	15
Effect of Altmetric score on manuscript citations: A randomized-controlled trial	15
No structural brain alterations in new daily persistent headache – a cross sectional VBM/SBM study	15
Clinical correlates of hypothalamic functional changes in migraine patients	15
Smooth muscle ATP-sensitive potassium channels mediate migraine-relevant hypersensitivity in mouse models	15
Effectiveness of physiotherapy interventions on headache intensity, frequency, duration and quality of life of patients with tension-type headache. A systematic review and network meta-analysis	14
Reversible cerebral vasoconstriction syndrome developing after an erenumab injection for migraine prevention	14
Muscle endurance training of the neck triggers migraine attacks	14
Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study	14
Poor social support and loneliness in chronic headache: Prevalence and effect modifiers	14
Time to retire ‘New daily persistent headache’: Mode of onset of chronic migraine and tension-type headache	14
Effect of K_ATP channel blocker glibenclamide on PACAP38-induced headache and hemodynamic	14
Neurovascular contact plays no role in trigeminal neuralgia secondary to multiple sclerosis	14
Additional effects of pain neuroscience education combined with physiotherapy on the headache frequency of adult patients with migraine: A randomized controlled trial	14
Twenty-five years of triptans – a nationwide population study	13
Update in the understanding of new daily persistent headache	13
Identification of work accommodations and interventions associated with work productivity in adults with migraine: A scoping review	13
Measuring health-related quality of life in chronic headache: A comparative evaluation of the Chronic Headache Quality of Life Questionnaire and Headache Impact Test (HIT-6)	13
Photophobia and allodynia in persistent post-traumatic headache are associated with higher disease burden	13
Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials	13
Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education in migraine treatment. A systematic review and meta-analysis	13
Forecasting migraine with machine learning based on mobile phone diary and wearable data	12
Epidemiology, burden and clinical spectrum of cluster headache: a global update	12
Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study	12
Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine	12
Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan	12
Timing of headache after COVID-19 vaccines and its association with cerebrovascular events: An analysis of 41,700 VAERS reports	12
Migraine genetics: Status and road forward	12
Pain in the temple? Headache, muscle pain or both: A retrospective analysis	12
The time sequence of brain MRI findings in spontaneous intracranial hypotension	12
Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2	11
Headache characteristics and postoperative course in Chiari I malformation	11
Diagnosis, knowledge, perception, and productivity impact of headache education and clinical evaluation program in the workplace at an information technology company of more than 70,000 employees	11
Sex-related differences in cluster headache: A hospital-based study in Taiwan	11
Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial	11
Targeting reactive nitroxidative species in preclinical models of migraine	11
Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: A randomized controll	11
Efficacy of erenumab in chronic migraine patients with and without ictal allodynia	11
A population-based survey for disabling headaches in Greece: Prevalence, burden and treatment preferences	11
Cervical musculoskeletal impairments in the 4 phases of the migraine cycle in episodic migraine patients	11
Effect of single dose Erenumab on cortical responses evoked by cutaneous a-delta fibers: A pilot study in migraine patients	11
The molecular clock gene cryptochrome 1 (CRY1) and its role in cluster headache	11
Update on headache and brain tumors	11
Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial	11
Calcitonin receptor antibody validation and expression in the rodent brain	10
Trans-nasal high-flow dehumidified air in acute migraine headaches: A randomized controlled trial	10
Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies	10
Evaluation and treatment of headache associated with moyamoya disease – a narrative review	10
De novo protein synthesis is necessary for priming in preclinical models of migraine	10
A systematic evaluation of primary headache management apps leveraging behavior change techniques	10
PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation	10
Interim analysis of the Registry for Load and Management of Medication Overuse Headache (RELEASE): A multicenter, comprehensive medication overuse headache registry	10
New daily persistent headache: A systematic review and meta-analysis	10
Occipital ischaemic stroke after visual snow phenomenon – a case report	10
Long-term open-label and real-world studies of lasmiditan, ubrogepant, and rimegepant for the acute treatment of migraine attacks	10
Pain sensitivities predict prophylactic treatment outcomes of flunarizine in chronic migraine patients: A prospective study	10
Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response	10